Egyptian MTA

Phase 3Small molecule

CCairo University

Egyptian MTA is one of 6 small molecule programs targeting Indirect Pulp Cap. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Indirect Pulp CapRecruiting

Indirect Pulp CapPhase 3

Recruiting

Competition

Competitive Landscape

6 competitors in Indirect Pulp Cap

#DrugCompanyPhaseTrials

Biodentine

IIstanbul University

Phase 3

2 2

Egyptian MTA

CCairo University

Phase 3

1 3

Calcium Hydroxide

MMansoura University

Preclinical

2 4

Silver Diamine Fluoride

TThe University of Hong Kong

Preclinical

1 5

Mineral Trioxide Aggregate

JJordan University of Science and Technology

Preclinical

2 6

Theracal LC

PPostgraduate Institute of Dental Sciences Rohtak

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Indirect Pulp Cap1 trial

Comparison Between Egyptian MTA, Biodentine Versus Calcium Hydroxide as Indirect Pulp Capping Materials In Permanent Teeth

Recruiting·—·Phase 4·NCT06683833·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Egyptian MTA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Egyptian MTA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Egyptian MTA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cairo University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCairo University

Egyptian MTA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Indirect Pulp Cap1 trial

References

Drug Info

Quick Facts

Related News